First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective

Cancers

Folco Furiesi¹  Ignazio Martellucci¹  Alessandra Pascucci¹  Silvano Giorgi²  Pietro Rosellini³  Sandra Donnini⁴  Cristiana Bellan⁵  Lorenzo Leoncini⁵  Marina Ziche⁶  Andrea Spini⁷  Clément Mathieu⁷  Allison Singier⁷  Francesco Salvo⁷  Rosa Gini⁸  Giuseppe Roberto⁸ 

[1] Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy;Azienda USL Toscana Sud Est, 53100 Siena, Italy;CIC 1401, CIC Bordeaux, 33000 Bordeaux, France;Department of Life Sciences, University of Siena, 53100 Siena, Italy;Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy;Department of Medical Science, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy;INSERM, BPH, U1219, Team Pharmacoepidemiology, Université de Bordeaux, 33000 Bordeaux, France;Osservatorio di Epidemiologia, Agenzia Regionale di Sanità Toscana, 50141 Florence, Italy;

关键词: drug utilization;    immunotherapy;    NSCLC;    non-small cell lung cancer;    target therapy;    survival;   

DOI  :  10.3390/cancers13236129

来源: DOAJ

【 摘 要 】

(1) Purpose: To describe first-line pharmacotherapy and overall survival in non-resectable non-small cell lung cancer (nrNSCLC) patients by gender. (2) Methods: Incident cases of nrNSCLC recorded between 2009 and 2019 (cohort entry) in the pathology registry of the regional administrative healthcare database of Tuscany were identified. Records of antineoplastic therapies delivered up to 4 months following cohort entry were classified as chemotherapy, target therapies, immunotherapies, and undefined monoclonal antibodies. First-line treatment and survival of patients receiving drug treatment was described. Analyses were stratified according to histology, gender, and cohort entry year. (3) Results: 4393 incident cases of nrNSCLC were included. Women with non-squamous-NSCLC received target-therapy more frequently than men (14.9% vs. 6.5%). Immunotherapy incidence of use varied between 3.8% (2017) and 9.1% (2019). The 2-year survival rate increased over time: for non-squamous-NSCLC, it was 22.3% (2009–2011) and 30.6% (2018–2019), while for squamous-NSCLC, it was 13.5% and 22.5%, respectively. After multivariate analysis, a low reduction in mortality risk in 2018–2019 vs. 2009–2011 was found (non-squamous: HR: 0.95 CI95%: 0.92–0.98; squamous: HR: 0.94 CI95%: 0.90–0.98). Among non-squamous NSCLC, median survival was longer in women than in men (389 vs. 276 days). (4) Conclusion: In light of sex-related biomolecular differences, among non-squamous NSCLC, women received target-therapy more frequently than men. Survival seemed to slightly improve over the study period for both histologies, despite a poor reduction in mortality risk was still observed.

【 授权许可】

Unknown